Arrowhead Pharmaceuticals, Inc. (ETR:HDP1)
Germany · Delayed Price · Currency is EUR | Market Cap | 7.76B +75.3% |
| Revenue (ttm) | 586.01M +16.8% |
| Net Income | -280.06M |
| EPS | -2.00 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 292 |
| Open | 54.96 |
| Previous Close | 55.64 |
| Day's Range | 54.88 - 55.90 |
| 52-Week Range | 54.88 - 78.04 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 25, 2026 |
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ... [Read more]
Financial Performance
In fiscal year 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024.
Financial numbers in USD Financial StatementsNews
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in th...
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will fo...
Arrowhead Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A broad RNAi platform is driving expansion into multiple indications, with REDEMPLO launched for FCS and a major SHTG launch targeted for 2027. Recent pivotal trials showed strong efficacy and safety, while new programs in obesity, CNS, and dimer technology signal continued pipeline growth.
Arrowhead Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The conference highlighted strong early clinical data for dual gene knockdown in mixed hyperlipidemia, a differentiated and rapidly advancing triglyceride-lowering therapy, and a robust pipeline targeting CNS and metabolic diseases. Commercial execution is progressing well, with a focus on innovation and leveraging AI for discovery.
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's first investigati...
Arrowhead Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Recent clinical data for plozasiran in SHTG show strong efficacy and a differentiated safety profile, with positive physician feedback and a focus on high-risk patient segments. Launch preparations are advanced, pricing has been well received by payers, and the company is prioritizing full U.S. commercialization while keeping future pipeline options open.
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: 2026 Cantor G...
Arrowhead Pharmaceuticals Transcript: KOL event
Plozasiran demonstrated robust, sustained triglyceride and acute pancreatitis risk reduction in SHTG, with a favorable safety profile and strong commercial potential. The initial launch will target high-risk patients, supported by advanced regulatory and market readiness.
Arrowhead Pharmaceuticals Press release: KOL event
Arrowhead Pharmaceuticals issued a press release on August 31, 2026, disclosing material business information to investors.
Arrowhead Pharmaceuticals Slides: KOL event
Arrowhead Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 31, 2026.
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
PASADENA, Calif.--(BUSINESS WIRE)-- #arrowheadpharma--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adu...
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present important new data at the European Society of Cardiology Congress (ESC) in Munich...
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that people in Germany who live with a rare metabolic condition called Familial Chylomicronaemia Syndr...
Arrowhead Pharmaceuticals Earnings Call Transcript: Q3 2026
SHASTA-3/4 phase III trials showed strong efficacy and safety for plozasiran in SHTG, supporting a planned sNDA submission by year-end 2026. REDEMPLO prescriptions more than doubled, with expanding global approvals and a robust pipeline advancing. Cash reserves of $1.6B support ongoing launches and R&D.
Arrowhead Pharmaceuticals Quarterly report: Q3 2026
Arrowhead Pharmaceuticals has published its Q3 2026 quarterly earnings report on August 4, 2026.
Arrowhead Pharmaceuticals Earnings release: Q3 2026
Arrowhead Pharmaceuticals released its Q3 2026 earnings on August 4, 2026, summarizing the period's financial results.
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is host...
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has signed an agreement with an undisclosed third party to acquire a U.S. Food and D...
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 16, 2026, the Co...
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran,...
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran ...
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discus...
Arrowhead Pharmaceuticals Transcript: Investor update
The cardiometabolic pipeline leverages RNAi technology to address both rare and prevalent lipid disorders, with REDEMPLO already launched and multiple late-stage programs advancing. Key upcoming milestones include pivotal data for plozasiran and zodasiran, and first human data for the dual-targeting DIMER siRNA, all targeting significant unmet needs in hyperlipidemia and ASCVD.
Arrowhead Pharmaceuticals Slides: Investor update
Arrowhead Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Commission (EC) has formally granted marketing authorization for REDEMPLO®...